Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / *W EXP 99/99/999
-
Total 13F shares
-
1,320,515
-
Share change
-
-10,700
-
Total reported value
-
$18,754,055
-
Price per share
-
$14.25
-
Number of holders
-
11
-
Value change
-
+$115,750
-
Number of buys
-
3
-
Number of sells
-
3
Institutional Holders of NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 (NAMSW) as of Q4 2024
As of 31 Dec 2024,
NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 (NAMSW) was held by
11 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,320,515 shares.
The largest 10 holders included
Frazier Life Sciences Management, L.P., RA CAPITAL MANAGEMENT, L.P., Affinity Asset Advisors, LLC, Bain Capital Life Sciences Investors, LLC, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Laurion Capital Management LP, HRT FINANCIAL LP, WOLVERINE ASSET MANAGEMENT LLC, Vestcor Inc, and UBS Group AG.
This page lists
11
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.